Jamie Dananberg graduated with his BS and MD degrees from Tufts University in Boston in 1979 and 1983, respectively. His post-graduate medical training was conducted at the University of Michigan, Ann Arbor, where he moved into a faculty position in the Division of Endocrinology and Metabolism, Department of Internal Medicine. During his tenure, he was the Director of the Endocrinology Fellowship Training Program. He research focused on the cellular and molecular perturbations in endothelial function in diabetes.
In 1996, he moved to Eli Lilly and Company, first taking on a research position in the endocrine therapeutic area. He eventually led that group before moving into a position leading the global clinical pharmacology group at Lilly. Presently, he is the Vice President, Translational Medicine and Tailored Therapeutics. His current group at Lilly includes Global Clinical Pharmacology (conducting First-in-Man and Phase 1 studies as well as Clinical Biopharmaceutics studies within Phases 2, 3 and 4), Pharmacogenomics, Diagnostic and Experimental Medicine (Clinical Pathology), Laboratory for Experimental Medicine, and Translational Imaging.
In addition, he is an active member of the NIH-funded Indiana Clinical and Translational Science Institute, which integrates translational research at Indiana University School of Medicine, Purdue University, Notre Dame, and Indiana University - Bloomington.